Clinical trials · New York
Allergy clinical trials in New York
We’re tracking 37 recruiting allergy studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Westchester, New YorkAges 13–20 - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Great Neck, New YorkAges 18–65 - NCT05584488Recruiting
Study of immune and allergy patterns over time
This study follows people with suspected or known inherited immune/allergy problems by collecting health information and blood. It may help researchers understand how immune systems and allergies behave over time and support future studies.
New York, New YorkAges Up to 99 years - NCT05272241Recruiting
Asthma registry that helps researchers learn about asthma
This study enrolls people in specific cities to collect health information that helps researchers better understand asthma and how to recruit future studies. It may help by improving knowledge about asthma types and care in real-world settings.
New York, New YorkAges Any age - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
Manhasset, New YorkAges 18 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
New York, New YorkAges 18–55 - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
New York, New YorkAges 18–75 - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Stony Brook, New YorkAges Up to 2 days - NCT01186913Enrolling by invitation
Natural history study for severe combined immune deficiency (SCID)
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
Rochester, New YorkAges Any age - NCT07778459Recruiting
Liver transplant study for people with HIV
This study tests whether it's safe and effective for people with HIV to receive a liver transplant from a donor who also has HIV. It aims to expand access to transplants for people with HIV.
New York, New YorkAges 18 years+ - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
New York, New YorkAges 18–60 - NCT07757802RecruitingPhase 1
HIV vaccine nanoparticle and mRNA booster for healthy adults
This study tests a new HIV vaccine that uses tiny particles (nanoparticles) and an mRNA booster — similar to some COVID vaccines. The goal is to see if it is safe and helps your body fight HIV. It's for healthy adults who do not have HIV.
Rochester, New YorkAges 18–55 - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
New York, New YorkAges 3–13
Allergy trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting allergy studies listed above.
- 5013, Jacobi Medical Center Clinical Research Site
- 5040, SUNY Stony Brook Clinical Research Site
- 5114, Bronx Lebanon Hospital Center Clinical Research Site
- Columbia P&S CRS (Site#: 30329)
- Columbia University Irving Medical Center
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
- Columbia University Medical Center: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
- Columbia University Medical Center: Department of Medicine, Division of Rheumatology
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Allergy trials in other states
Common questions
- Are there allergy clinical trials in New York?
- Yes. We're currently tracking 37 recruiting allergy studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.